DOCSLIB.ORG

Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Succes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Succes Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Successfully Undergo Induction Chemotherapy: Follow-up Analysis of Data from 2006-2013 JC Hofmann, MD1,2; KM Grant, MD3; DD Kiprov, MD1,2 1Apheresis Care Group, 2Division of Immunotherapy, 3Division of Hematology, Department of Medicine, California Pacific Medical Center, San Francisco, California 1 Disclosure of Conflicts of Interest “Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Successfully Undergo Induction Chemotherapy” Jan Hofmann, MD has reported the following financial relationships with commercial interests related to the content of this educational activity: Consulting Fees: Fresenius Medical Care 2 Hematologic Diseases (ASFA 2013 Categories) Disease Category Rec. Grade • Primary, idiopathic TTP I 1A • Thrombotic microangiopathy (TMA): - Ticlopidine I 1B - Clopidogrel III 2B - Cyclosporine/Tacrolimus III 2C - Gemcitabine IV 2C - HSCT-associated (refractory) III 1B • Hyperviscosity (monoclonal gammopathies) I 1B • Catastrophic Antiphospholipid Syndrome (CAPS) II 2C • Hyperleukocytosis: - Leukostasis (WBC depletion) I 1B - Prophylaxis (AML; ALL, if WBC>400K) III 2C • Sickle cell disease: - acute CVA (RBCX) I 1C - acute chest syndrome (RBCX) II 1C • Malaria (severe falciparum malaria; RBCX) II 2B 3 Acute Leukemia (with hyperleukocytosis): • Hyperleukocytosis: • Circulating WBC or leukemic blast cell count >100 X 109/L (>100K) • Acute Myelogenous Leukemia (AML): very large, stiff myeloblasts • Acute Lymphoblastic Leukemia (ALL): lg., deformable lymphoblasts • Leukostasis (clinical presentation): hyperviscosity, microvascular leukoaggregates, tissue ischemia, infarction/thrombosis, hemorrhage: • CNS symptoms (confusion, somnolence, delirium, coma, hemorrhage) • Pulmonary complications (dyspnea, hypoxemia, respiratory failure, diffuse alveolar hemorrhage, pulmonary infiltrates). • AML myeloblasts ( endothelial adhesion molecule expression) • AML (WBC >100K; occas. >50K); ALL (WBC >400K) 4 Acute Leukemia: treatment options • Treatment: • Definitive induction chemotherapy; hydroxyurea • Management of tumor lysis syndrome: intravenous fluid, allopurinol or rasburicase, electrolyte replacement, alkalinization of urine, dialysis. • Avoid RBC transfusions ( cell mass); FFP, platelet transfusions PRN • Leukocytapheresis: • Treatment of leukocytosis/leukostasis (“surgical debulking”) • May metabolic sequellae of tumor cell lysis syndrome • ASFA Cat. I (leukostasis); ASFA Cat. III (prophylaxis) • Indication for leukocytapheresis: - Clinical evidence of leukostasis; blast crisis; hyperleukocytosis - Blast crisis: blast cells >75% or blast cell count >100K 5 Acute Leukemia: Suggested Leukocytapheresis Goals • Daily leukocytapheresis until patient reaches WBC goal (before initiation of definitive chemotherapy): usually 1-3 treatments: • ASFA recommendations: treatment goals: - AML: asymptomatic pts: WBC <100K symptomatic pts: WBC <50K & no leukostasis sxs - ALL: asymptomatic pts: WBC <400K symptomatic pts: WBC <400K & no leukostasis sxs 6 Acute Leukemias: AML Acute Myelogenous Leukemia: • WBC ~100-300K: pts present with leukostasis (CNS &/or resp.) sxs • Myeloblasts: very large, stiff, non-deformable, tend to adhere to each other causing WBC thrombi at lower WBC counts. • WBC 45-60% per treatment • Usually 1-3 leukapheresis txs to reach WBC goal • Recommend post-tx CBC (assess immediate WBC): - rarely rebound in WBC: minimal to no splenomegaly 7 Acute Leukemias: ALL Acute Lymphoblastic Leukemia: • WBC ~250-550K: pts present with leukostasis (CNS &/or resp.) sxs • Lymphoblasts: large, deformable, tend to adhere less to each other, only causing WBC thrombi at higher WBC counts. • WBC 35-45% per treatment • Usually 1-4 leukapheresis txs to reach WBC goal • Recommend post-tx CBC (assess immediate WBC): - often notable rebound in WBC because of moderate splenomegaly 8 Leukocytapheresis (WBC sequestration & rebound) Leukocytapheresis Leukocytapheresis 1000K 560K Chemo 500K WBC 470K 380K Platelets PRBC 0 Time 22:00 01:30 11:00 14:00 12 y.o. pt with ALL: WBC 780K (60% blasts), resp. distress, confusion, spleen 5 cm RCM. S. Torloni, Mayo Clinic, Scottsdale, AZ 9 WBC Depletion in Acute Leukemia: Evidence from the literature (1) Safety & effectiveness of leukocytapheresis in AML & ALL (~18 case series, cohort studies, or controlled trials); no RCTs: • Bug et al (2007): retrospective, cohort study (53 pts with AML): - 25 pts: chemotherapy (Ch) vs. 28 pts: Ch + leukapheresis (Lp) - risk of early death (21 days): Ch + Lp group (16%) vs. Ch group (32%) - median survival similar: Ch + Lp group (7.5 mos.); Ch group (6.5 mos.) • Giles et al (2001): retrospective, cohort study (146 pts with AML): - 75 pts (Ch alone) vs. 71 pts (Ch + Lp) - risk of early death (14 days): Ch + Lp group (13%) vs. Ch group (23%) - median CR similar: Ch + Lp group (62%) vs. Ch group (59%) 10 WBC Depletion in Acute Leukemia: Evidence from the literature (2) • Chang et al (2007): retrospective, cohort study (75 pts with AML): - 37 pts (Ch) vs. 38 pts (Ch + Lp [22] or cranial irrad. [10] or both [6]) - risk of death (30 d): Ch/Lp/CI group (40%) vs. Ch group (27%) - mean survival: Ch/Lp/CI group (10.6 mos.) vs. Ch group (34.8 mos.) - WBC>200K: Ch/Lp/CI group (34%) vs. Ch group (16%) - ≥ 2 sxs of leukostasis: Ch/Lp/CI group (32%) vs. Ch group (16%) • Thiebaut et al (2000): retrospective, case series (53 pts with AML): - 53 pts (Lp +/- Ch); median # txs = 1 (1-4 txs); early death (7 days): 3.8% - low level of early death 96% (51/53) pts received induction chemo. 11 WBC Depletion in Acute Leukemia: Evidence from the literature (3) Summary: • Leukapheresis appears to decrease short-term mortality rate; does not increase overall survival. • Pts selected for leukapheresis treatment are often sicker and have a higher underlying mortality rate. • Leukapheresis appears to be helpful to survive blast crisis and start induction chemotherapy. Bruserud O et al. Transfus Med 2013; 23 (6): 397-406. Hofmann JC et al. Blood 2011; 118 (21): abstr 4281. Bug G et al. Transfusion 2007; 47: 1843-1850. Lowe EJ et al. Pediatr Blood Cancer 2005; 45: 10-15. Chang MC et al. Am J Hematol 2007; 82 (11): 976-980. Porcu P et al. Ther Apher 2002; 6: 15-23. Blum W, Porcu P. Semin Thromb Hemost 2007; 33 (4): 350-54. Giles FJ et al. Leuk Lymphoma 2001; 42: 67-73. Novotny JR et al. Eur J Haematol 2005; 74: 501-510. Thiebaut A et al. Ann Hematol 2000; 79: 501-506. 12 AML & ALL patients (1/06-9/13) • 1/06-9/13: 3,164 patients (pts); 24,708 apheresis treatments (txs) • Acute leukemia (AML or ALL): 231 pts (7.3%); 593 txs (2.4%) - AML: 143 pts (4.5%); 320 leukocytapheresis txs - ALL: 88 pts (2.8%); 273 leukocytapheresis txs • Retrospective, case series: - Blast crisis: blast cells >75% or blast cell count >100K - Leukostasis symptoms (sxs): CNS and/or pulmonary manifestations - Goals: AML pts: WBC <55K & resolution of leukostasis sxs ALL pts: WBC <80-100K & resolution of leukostasis sxs - Outcomes scale: improved; stabilized; unchanged - Improved: attain WBC goal & resolution of leukostasis sxs - Stabilized: attain >50% reduction in WBC & resolution of sxs - Unchanged: attain neither WBC level; no resolution of sxs 13 AML patients (ACG database: 1/06-9/13) AML (143 pts; 320 txs): • Median initial WBC: 213K (range 66-427K); final WBC: 53K (17-137K) • Median # txs: 2 (mean 2.2 txs/pt; range 1-5 txs); WBC 45-60% per tx • Median age: 52 years old (y.o.) (6-85 y.o.); <20 y.o. (13%) • Blast crisis: 89%; Leukostasis sxs: 0 sxs (11%), 1 sx (53%), 2 sxs (36%) • Outcome: Improved (73%); stabilized (25%); unchanged (2%) • Received induction chemotherapy: 91% pts • Expired pts: 12 pts (8.4%) expired w/i 1-4 days after completing txs: - blast crisis (83%); 2 sxs leukostasis (75%); prior ICH or CVA (42%) - ventilated/hypotensive (100%); unable to tolerate chemotherapy (92%) • Non-treated pts: 17 additional pts: - 11 pts: stabilized/received induction chemotherapy - 6 pts: too unstable to treat (all expired within 24 hours) 14 ALL patients (ACG database: 1/06-9/13) ALL (88 pts; 273 txs): • Median initial WBC: 341 (range 104-764K); final WBC: 77K (30-297K) • Median # txs: 2 (mean 3.1 txs/pt, range 1-7 txs); WBC 35-45% per tx • Median age: 19 years old (y.o.) (3-80 y.o.); <20 y.o. (36%) • Blast crisis: 84%; Leukostasis sxs: 0 sxs (21%), 1 sx (65%), 2 sxs (14%) • Outcome: Improved (61%); stabilized (36%); unchanged (3%) • Received induction chemotherapy: 97% pts • Expired pts: 2 pt (2.3%) expired w/i 1 day after completing treatments: + blast crisis, 2 sxs leukostasis, prior ICH, ventilated/hypotensive + unable to tolerate chemotherapy • Non-treated pts: 4 additional pts: - 3 pts: stabilized/received induction chemotherapy - 1 pt: too unstable to treat (expired within 24 hours) 15 Study Limitations • Retrospective, case series (not cohort or prospective study) • Lack of long-term outcome data • Some ALL patients may have been overtreated 16 Summary: Hyperleukocytosis, leukostasis, and WBC depletion • Carefully selected patients with acute leukemia (and evidence of impending thrombosis) appear to benefit significantly from WBC depletion. • A limited number of treatments (median 2 treatments) can enable a high percentage of patients to receive induction chemotherapy, improves short-term clinical outcomes, and is critical to allow patients to proceed to definitive treatment. • A randomized controlled trial to assess efficacy of
Load more

Recommended publications
  • Pathologic Rupture of the Spleen in a Patient with Acute Myelogenous Leukemia and Leukostasis
    rev bras hematol hemoter. 2014;36(4):290–292 Revista Brasileira de Hematologia e Hemoterapia Brazilian Journal of Hematology and Hemotherapy www.rbhh.org Case report Pathologic rupture of the spleen in a patient with acute myelogenous leukemia and leukostasis Gil Cunha De Santis ∗, Luciana Correa Oliveira, Aline Fernanda Ramos, Nataly Dantas Fortes da Silva, Roberto Passetto Falcão Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil article info abstract Article history: Rupture of the spleen can be classified as spontaneous, traumatic, or pathologic. Patho- Received 14 October 2013 logic rupture has been reported in infectious diseases such as infectious mononucleosis, Accepted 14 January 2014 and hematologic malignancies such as acute and chronic leukemias. Splenomegaly is con- Available online 28 May 2014 sidered the most relevant factor that predisposes to splenic rupture. A 66-year-old man with acute myeloid leukemia evolved from an unclassified myeloproliferative neoplasm, Keywords: complaining of fatigue and mild upper left abdominal pain. He was pale and presented Splenomegaly fever and tachypnea. Laboratory analyses showed hemoglobin 8.3 g/dL, white blood cell 9 9 Leukemia count 278 × 10 /L, platelet count 367 × 10 /L, activated partial thromboplastin time (aPTT) Myeloid ratio 2.10, and international normalized ratio (INR) 1.60. A blood smear showed 62% of Acute myeloblasts. The immunophenotype of the blasts was positive for CD117, HLA-DR, CD13, Leukostasis CD56, CD64, CD11c and CD14. Lactate dehydrogenase was 2384 U/L and creatinine 2.4 mg/dL (normal range: 0.7–1.6 mg/dL). Two sessions of leukapheresis were performed. At the end of the second session, the patient presented hemodynamic instability that culminated in cir- culatory shock and death.
    [Show full text]
  • Cells, Tissues and Organs of the Immune System
    Immune Cells and Organs Bonnie Hylander, Ph.D. Aug 29, 2014 Dept of Immunology [email protected] Immune system Purpose/function? • First line of defense= epithelial integrity= skin, mucosal surfaces • Defense against pathogens – Inside cells= kill the infected cell (Viruses) – Systemic= kill- Bacteria, Fungi, Parasites • Two phases of response – Handle the acute infection, keep it from spreading – Prevent future infections We didn’t know…. • What triggers innate immunity- • What mediates communication between innate and adaptive immunity- Bruce A. Beutler Jules A. Hoffmann Ralph M. Steinman Jules A. Hoffmann Bruce A. Beutler Ralph M. Steinman 1996 (fruit flies) 1998 (mice) 1973 Discovered receptor proteins that can Discovered dendritic recognize bacteria and other microorganisms cells “the conductors of as they enter the body, and activate the first the immune system”. line of defense in the immune system, known DC’s activate T-cells as innate immunity. The Immune System “Although the lymphoid system consists of various separate tissues and organs, it functions as a single entity. This is mainly because its principal cellular constituents, lymphocytes, are intrinsically mobile and continuously recirculate in large number between the blood and the lymph by way of the secondary lymphoid tissues… where antigens and antigen-presenting cells are selectively localized.” -Masayuki, Nat Rev Immuno. May 2004 Not all who wander are lost….. Tolkien Lord of the Rings …..some are searching Overview of the Immune System Immune System • Cells – Innate response- several cell types – Adaptive (specific) response- lymphocytes • Organs – Primary where lymphocytes develop/mature – Secondary where mature lymphocytes and antigen presenting cells interact to initiate a specific immune response • Circulatory system- blood • Lymphatic system- lymph Cells= Leukocytes= white blood cells Plasma- with anticoagulant Granulocytes Serum- after coagulation 1.
    [Show full text]
  • Hyperleukocytosis (Re)Visited- Is It Case Series Always Leukaemia: a Report of Two Pathology Section Cases and Review of Literature Short Communication
    Review Article Clinician’s corner Original Article Images in Medicine Experimental Research Miscellaneous Letter to Editor DOI: 10.7860/JCDR/2020/40556.13409 Case Report Postgraduate Education Hyperleukocytosis (Re)Visited- Is it Case Series always Leukaemia: A Report of Two Pathology Section Cases and Review of Literature Short Communication ASHUTOSH RATH1, RICHA GUPTA2 ABSTRACT Hyperleukocytosis is defined as total leukocyte count of more than 100×109/L. Commonly seen in leukaemic conditions, non- leukaemic causes are usually not encountered and thought of. We report two such non-malignant cases of hyperleukocytosis. A six-year old girl presented with fever, cough and respiratory distress with a leukocyte count of 125.97×109/L. Another case is of a two-month old female infant, who presented with fever and respiratory distress and a leukocyte count of 112.27×109/L. The present case thrives to highlight various possible causes of hyperleukocytosis with an emphasis on non-malignant causes. Also, important complications and management of hyperleukocytosis are discussed. Keywords: Benign, Leukocytosis, Leukostasis CASE REPORT 1 for methicillin-resistant Staphylococcus aureus and was started A six-year-old girl was admitted with complaints of fever, non- on intravenous Vancomycin along with supportive care. Serial productive cough for one week and severe respiratory distress for monitoring of TLC revealed a gradual reduction and it returned to the the past one day. There was no other significant history. On physical baseline of 15×109/L after eight days. The patient was discharged examination, the patient had mild pallor. Respiratory examination after 10 days of hospital stay.
    [Show full text]
  • Novel Emergency Medicine Curriculum Utilizing Self- Directed Learning and the Flipped Classroom Method: Hematologic/Oncologic Emergencies Small Group
    CURRICULUM Novel Emergency Medicine Curriculum Utilizing Self- Directed Learning and the Flipped Classroom Method: Hematologic/Oncologic Emergencies Small Group Module Michael G Barrie, MD*, Chad L Mayer, MD*, Colin Kaide, MD*, Emily Kauffman, DO*, Jennifer Mitzman, MD*, Matthew Malone, MD*, Daniel Bachmann, MD*, Ashish Panchal, MD*, Howard Werman, MD*, Benjamin Ostro, MD* and Andrew King, MD* *The Ohio State University Wexner Medical Center, Department of Emergency Medicine, Columbus, OH Correspondence should be addressed to Andrew King, MD, FACEP at [email protected], Twitter: @akingermd Submitted: August 6, 2018; Accepted: November 21, 2018; Electronically Published: January 15, 2019; https://doi.org/10.21980/J8VW56 Copyright: © 2019 Barrie, et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/ ABSTRACT: Audience: This curriculum, created and implemented at The Ohio State University Wexner Medical Center, was designed to educate our emergency medicine (EM) residents, intern to senior resident level, as well as medical students and attending physicians. Introduction: Disorders of the hematologic system represent a wide spectrum of disease, including bleeding disorders, coagulopathies, blood cell disorders, and oncology related disorders. Hematologic related problems often complicate other disease processes, including malignancy. The number of patients diagnosed with malignancy is increasing due to many factors, including, but not limited to, an aging population and the increased ability for early detection.1 Patients with oncologic conditions can present in a variety of ways with a variety of complications,2 and understanding the steps in diagnosis and management are important components of any emergency physician’s training.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Original Article Anemia, Leukocytosis and Eosinophilia in a Resource-Poor
    Original Article Anemia, leukocytosis and eosinophilia in a resource-poor population with helmintho-ectoparasitic coinfection Daniel Pilger1, Jörg Heukelbach2, Alexander Diederichs1, Beate Schlosser1, Cinthya Pereira Leite Costa Araújo3, Anne Keysersa1, Oliver Liesenfeld1, Hermann Feldmeier1 1Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Institute of Microbiology and Hygiene, D-12203 Berlin, Germany 2Department of Community Health, School of Medicine, Federal University of Ceará, Fortaleza, CE 60430-140, Brazil 3Department of Hematology, Estate University of Health Science of Alagoas, Alagoas, CEP 57010-300, Brazil Abstract Introduction: Eosinophilia and anemia are very common hematological alterations in the tropics but population-based studies scrutinizing their value for diagnosing parasitic infections are rare. Methodology: A cross-sectional study was conducted in a rural district in northeast Brazil where parasitic infections are common. Stool and blood samples were collected and individuals were clinically examined for the presence of ectoparasites. Results: In total, 874 individuals were examined. Infection with intestinal helminths occurred in 70% (95% CI 67 – 75), infestation with ectoparasites in 45% (95% CI 42 - 49) and co-infection with both helminths and ectoparasites was found in 33% (95% CI 29% - 36%) of all inhabitants. Eosinophil counts ranged from 40/µl to 13.800/µl (median: 900/µl). Haemoglobin levels ranged from 4.8 g/dl to 16.8 g/dl (median: 12.5 g/dl), and anemia was present in 24% of the participants. Leukocytosis was found in 13%, eosinophilia in 74%, and hypereosinophilia in 44% of the participants. Eosinophilia was more pronounced in individuals co-infected with intestinal helminths and ectoparasites (p < 0.001) and correctly predicted parasitic infection in 87% (95% CI 84%-90.7%) of all cases.
    [Show full text]
  • Hemodialysis Leukopenia. Pulmonary Vascular Leukostasis Resulting from Complement Activation by Dialyzer Cellophane Membranes
    Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. P R Craddock, … , K L Brighan, H S Jacob J Clin Invest. 1977;59(5):879-888. https://doi.org/10.1172/JCI108710. Research Article Acute leukopenia occurs in all patients during the first hour of hemodialysis with cellophanemembrane equipment. This transient cytopenia specifically involves granulocytes and monocytes, cells which share plasma membrane reactivity towards activated complement components. The present studies document that complement is activated during exposure of plasma to dialyzer cellophane, and that upon reinfusion of this plasma into the venous circulation, granulocyte and monocyte entrapment in the pulmonary vasculature is induced. During early dialysis, conversion of both C3 and factor B can be demonstrated in plasma as it leaves the dialyzer. Moreover, simple incubation of human plasma with dialyzer cellophane causes conversion of C3 and factor B, accompanied by depletion of total hemolytic complement and C3 but sparing of hemolytic C1. Reinfusion of autologous, cellophane-incubated plasma into rabbits produces selective granulocytopenia and monocytopenia identical to that seen in dialyzed patients. Lungs from such animals reveal striking pulmonary vessel engorgement with granulocytes. The activated complement component(s) responsible for leukostasis has an approximate molecular weight of 7,000-20,000 daltons. Since it is generated in C2-deficient plasma and is associated with factor B conversion, it is suggested that activation of complement by dialysis is predominantly through the altermative pathway. Find the latest version: https://jci.me/108710/pdf Hemodialysis Leukopenia PULMONARY VASCULAR LEUKOSTASIS RESULTING FROM COMPLEMENT ACTIVATION BY DIALYZER CELLOPHANE MEMBRANES PHILIP R.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]
  • Leukocytosis & Lymphocytosis
    Leukocytosis Leukocytosis >11 (Repeated) Blood Smear AND History & EMERGENT REFERRAL Refer to Blasts on Smear Physical Exam Lymphocytes >4 Page Hematologist On-Call Lymphocytosis Algorithm Include nodes and spleen Myeloid Cells Basophils Monocytes Neutrophils Eosinophils CONCERNING FEATURES CONCERNING FEATURES CONCERNING FEATURES » Count >2 or increasing, or persistent » Count >50 » Count >2 or increasing or persistent » Not explained by infection » Promyelocytes and myelocytes » Dysplasia YES » Dysplasia » Dysplasia YES » Anemia » Immature forms » Basophilia » New organ damage » Anemia/thrombo-cytopenia » Splenomegaly » NOT explained by infection, allergies » Splenomegaly » NOT associated with acute infection or collagen vascular disease NO NO NO Consider Consider » Cancer Reactive Causes » drugs NO » Collagen VD YES e.g. Infection / inflammation, NO NO » Infections YES » Chronic infection autoimmune, drugs esp. steroids » Allergies » Marrow recovery » Collagen Vascular Disease Refer to Hematology Treat and Observe for recovery Refer to Hematology Treat and Observe for recovery © Blood Disorder Day Pathways are subject to clinical judgement and actual practice patterns may not always follow the proposed steps in this pathway. Lymphocytosis Lymphocytosis >4 (Repeated) Concerning Features “Reactive” Lymphocytes Asymptomatic » Lymphocytes >30 Patient symptoms of infection or acute illness » Hgb <100 » Night sweats/ weight loss » Splenomegaly Flow Cytometry AND Flow Cytometry IF PERSISTENT Work-up for secondary causes »Immunization »Viral
    [Show full text]
  • 1. Introduction to Immunology Professor Charles Bangham ([email protected])
    MCD Immunology Alexandra Burke-Smith 1. Introduction to Immunology Professor Charles Bangham ([email protected]) 1. Explain the importance of immunology for human health. The immune system What happens when it goes wrong? persistent or fatal infections allergy autoimmune disease transplant rejection What is it for? To identify and eliminate harmful “non-self” microorganisms and harmful substances such as toxins, by distinguishing ‘self’ from ‘non-self’ proteins or by identifying ‘danger’ signals (e.g. from inflammation) The immune system has to strike a balance between clearing the pathogen and causing accidental damage to the host (immunopathology). Basic Principles The innate immune system works rapidly (within minutes) and has broad specificity The adaptive immune system takes longer (days) and has exisite specificity Generation Times and Evolution Bacteria- minutes Viruses- hours Host- years The pathogen replicates and hence evolves millions of times faster than the host, therefore the host relies on a flexible and rapid immune response Out most polymorphic (variable) genes, such as HLA and KIR, are those that control the immune system, and these have been selected for by infectious diseases 2. Outline the basic principles of immune responses and the timescales in which they occur. IFN: Interferon (innate immunity) NK: Natural Killer cells (innate immunity) CTL: Cytotoxic T lymphocytes (acquired immunity) 1 MCD Immunology Alexandra Burke-Smith Innate Immunity Acquired immunity Depends of pre-formed cells and molecules Depends on clonal selection, i.e. growth of T/B cells, release of antibodies selected for antigen specifity Fast (starts in mins/hrs) Slow (starts in days) Limited specifity- pathogen associated, i.e.
    [Show full text]
  • Therapeutic Leukapheresis in Patients with Leukostasis Secondary to Acute Myelogenous Leukemia
    Journal of Clinical Apheresis 26:181–185 (2011) Therapeutic Leukapheresis in Patients with Leukostasis Secondary to Acute Myelogenous Leukemia Gil Cunha De Santis,1 Luciana Correa Oliveira de Oliveira,1,2*y Lucas Gabriel Maltoni Romano,3 Benedito de Pina Almeida Prado Jr.,1 Belinda Pinto Simoes,1,2 Eduardo Magalhaes Rego,1,2 Dimas Tadeu Covas,1,2 and Roberto Passetto Falcao1,2 1Center for Cell Based Therapy, Medical School of Ribeirao Preto, University of Sao Paulo, Brazil 2Department of Internal Medicine, Hematology Division, Medical School of Ribeirao Preto, University of Sao Paulo, Brazil 3Medical School of Ribeirao Preto, University of Sao Paulo, Brazil Leukostasis is a relatively uncommon but potentially catastrophic complication of acute myelogenous leukemia (AML). Prompt leukoreduction is considered imperative to reduce the high mortality rate in this condition. Leu- kapheresis, usually associated with chemotherapy, is an established approach to diminish blast cell counts. We report a single center experience in managing leukostasis with leukapheresis. Fifteen patients with leukostasis of 187 patients with AML (8.02%) followed at our institution were treated with leukapheresis associated with chem- otherapy. The procedures were scheduled to be performed on a daily basis until clinical improvement was achieved and WBC counts were significantly reduced. Overall and early mortalities, defined as that occurred in the first 7 days from diagnosis, were reported. A high proportion of our patients with leukostasis (46.66%) had a monocytic subtype AML (M4/M5, according to French-American-British classification). The median overall sur- vival was 10 days, despite a significant WBC reduction after the first apheresis procedure (from 200.7 3 109/L to 150.3 3 109/L).
    [Show full text]
  • Exotics Oncology: Special Focus on Updates on Therapies for Rabbits & Ferrets
    Exotics Oncology: Special Focus on Updates on Therapies for Rabbits & Ferrets La’Toya Latney, DVM Exotic Companion Animal Medicine Service Penn Vet THYMOMAS IN RABBITS Rabbits possess a persistent thymus, which does not involute with age. The thymus is comprised of thymic epithelium, reticuloendothelial tissue, and lymphoid tissue. Primary thymic neoplasms recognized in rabbits include (1) benign neoplasm of thymic epithelial cells, (2) thymic carcinoma, a rare malignant neoplasm of the epithelial cells and (3) thymic lymphoma, which is a malignant neoplasm of the lymphoid tissue of the thymus. Clinically, thymomas are diagnosed as lymphoid-rich, epithelial-rich, or mixed lymphoepithelial. The incidence in pet rabbits is largely unknown, however in one retrospective study, thymomas comprised 7% of all neoplasms in 55 colony rabbits in rabbits 2-4 years of age in 1949. More recently, in a retrospective evaluation of 1,100 female rabbits more than 2 years of age submitted for necropsy over a 17-year period, 4 cases of the 234 rabbits that had neoplasia were thymomas (Andres 2012). Literary resources are mainly comprised of clinical case reports (Guzman, Kunzel, Pilny, Bennett, Kovalik, Wagner, Quesenberry, Florizoone, Vernau). Based on current literature, there is no specific sex predisposition, but the common age range is 3-10 years of age, with the median age of 6 years (Kunzel, Andres). Certain breeds have been consistently prominent in clinical case reports, including Netherland dwarves and Lionhead rabbits (Kunzel, Andres). Clinical signs commonly include severe dyspnea and nasal flaring, third eyelid protrusion, orthopneic body position, and bilateral exophthalmos due to caval compression resulting in the pooling of blood in retrobulbar venous plexus.
    [Show full text]